AllianceBernstein
AXSM icon

AllianceBernstein’s Axsome Therapeutics AXSM Stock Holding History

AllianceBernstein’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Buy
62,822
+9,682
+18% +$1.67M ﹤0.01% 1140
2025
Q4 		$9.71M Sell
53,140
-9,925
-16% -$1.39M ﹤0.01% 1237
2025
Q3 		$7.66M Buy
63,065
+17,083
+37% +$1.92M ﹤0.01% 1336
2025
Q2 		$4.8M Sell
45,982
-15,489
-25% -$1.64M ﹤0.01% 1497
2025
Q1 		$7.17M Buy
61,471
+14,881
+32% +$1.7M ﹤0.01% 1309
2024
Q4 		$3.94M Sell
46,590
-78,388
-63% -$7.21M ﹤0.01% 1596
2024
Q3 		$11.2M Sell
124,978
-43,784
-26% -$3.82M ﹤0.01% 1126
2024
Q2 		$13.6M Buy
168,762
+88,608
+111% +$6.56M ﹤0.01% 1020
2024
Q1 		$6.4M Buy
80,154
+38,864
+94% +$3.26M ﹤0.01% 1375
2023
Q4 		$3.29M Hold
41,290
– – ﹤0.01% 1682
2023
Q3 		$2.89M Buy
41,290
+590
+1% +$44.1K ﹤0.01% 1686
2023
Q2 		$2.92M Hold
40,700
– – ﹤0.01% 1688
2023
Q1 		$2.51M Hold
40,700
– – ﹤0.01% 1739
2022
Q4 		$3.14M Hold
40,700
– – ﹤0.01% 1653
2022
Q3 		$1.82M Hold
40,700
– – ﹤0.01% 1950
2022
Q2 		$1.56M Buy
40,700
+700
+2% +$22.1K ﹤0.01% 2098
2022
Q1 		$1.66M Buy
40,000
+3,400
+9% +$105K ﹤0.01% 2200
2021
Q4 		$1.38M Sell
36,600
-4,200
-10% -$155K ﹤0.01% 2344
2021
Q3 		$1.34M Hold
40,800
– – ﹤0.01% 2380
2021
Q2 		$2.75M Sell
40,800
-599,585
-94% -$36M ﹤0.01% 1987
2021
Q1 		$36.3M Buy
640,385
+42,587
+7% +$3M 0.02% 716
2020
Q4 		$48.7M Buy
597,798
+55,525
+10% +$4.15M 0.02% 594
2020
Q3 		$38.6M Buy
542,273
+86,071
+19% +$6.71M 0.02% 611
2020
Q2 		$37.5M Buy
456,202
+156,411
+52% +$12M 0.02% 601
2020
Q1 		$17.6M Buy
299,791
+31,966
+12% +$2.6M 0.01% 727
2019
Q4 		$27.7M Sell
267,825
-498,354
-65% -$20.1M 0.02% 710
2019
Q3 		$15.5M Sell
766,179
-4,691
-0.6% -$121K 0.01% 885
2019
Q2 		$19.9M Buy
+770,870
New +$15.5M 0.01% 807

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's AXSM Position: Q1 2026 in Review

AllianceBernstein increased its Axsome Therapeutics (AXSM) stake by 18% in Q1 2026, buying an estimated $1.67M and bringing the position to 62,822 shares worth $11.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

AllianceBernstein first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $48.7M in Q4 2020. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • AllianceBernstein held 62,822 shares of Axsome Therapeutics worth $11.5M as of Q1 2026.
  • AllianceBernstein bought 9,682 Axsome Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Axsome Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1140 holding.
  • AllianceBernstein first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • AllianceBernstein's Axsome Therapeutics position peaked at $48.7M in Q4 2020.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.